N/A
Completed N=68
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Virus Diseases · Herpes Zoster
Source: ClinicalTrials.gov NCT00921934 ↗
Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcomePrimary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity
Summary
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.
Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change of Pain Measured by VAS |
5.8; 2.2; 0.6; 1.2 | — |
Eligibility Criteria
Due to the design of an Observational Cohort Study, no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".
Observational Criteria:
- adult patients
- acute viral infection (especially herpes zoster)
- Primary Care patient
- eligible for add-on therapy with vitamin C
- willingness to provide pseudonymized data to the Sponsor
Data sourced from ClinicalTrials.gov (NCT00921934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.